<p>BAIYUNSHAN PH (00874.HK) announced its 2025 annual results, with operating revenue of RMB 77.656 billion, an increase of 3.6% year-on-year. The net profit attributable to shareholders was RMB 2.983 billion, a growth of 5.2%, with earnings per share of RMB 1.835. A final dividend of 45 cents was declared</p>

589720

159859

159506

<p>BAIYUNSHAN PH announced its 2025 annual performance, with operating revenue of 77.656 billion RMB (same below), an increase of 3.6% year-on-year. The net profit attributable to shareholders is 2.983 billion RMB, a growth of 5.2%, with earnings per share of 1.835 RMB. The final dividend is 0.45 RMB</p>

AASTOCKS

Guotai SSE STAR Brand Name Drug ETF

Tianhong CNI BIOMEDICINE ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

GYBYS

Yinhua CSI Innovative Drugs Industry ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

BAIYUNSHAN PH

Huaan Hang Seng Biotech ETF

Penghua SSE STAR Biology and Medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

China Merchants CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal 800 Health Care ETF

E Fund CSI 300 Health Care ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

Guotai CSI Bio-medicine ETF

"Performance" Baiyunshan's annual net profit is 2.983 billion RMB, an increase of 5.2%, with a final dividend of 0.45 yuan